Azitra, Inc. (NYSEAMERICAN:AZTR – Free Report) – Equities researchers at Zacks Research issued their Q2 2026 earnings estimates for Azitra in a research note issued on Friday, May 22nd. Zacks Research analyst J. Vandermosten expects that the company will post earnings per share of ($0.21) for the quarter. The consensus estimate for Azitra’s current full-year earnings is ($0.71) per share. Zacks Research also issued estimates for Azitra’s Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.04) EPS and FY2028 earnings at ($0.08) EPS.
Azitra (NYSEAMERICAN:AZTR – Get Free Report) last announced its earnings results on Wednesday, May 13th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.24).
Azitra Stock Up 3.0%
About Azitra
Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.
The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.
Read More
- Five stocks we like better than Azitra
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Receive News & Ratings for Azitra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azitra and related companies with MarketBeat.com's FREE daily email newsletter.
